Mirabegron
Mirabegron, sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder. Its benefits are similar to antimuscarinic medication such as solifenacin or tolterodine. It is taken by mouth.Common side effects include high blood pressure, headaches, and urinary tract infections. Other significant side effects include urinary retention, irregular heart rate, and angioedema. It works by activating the β3 adrenergic receptor in the bladder, resulting in its relaxation.Mirabegron is the first clinically available beta-3 agonist with approval for use in adults with overactive bladder. Mirabegron was approved for medical use in the United States and in the European Union in 2012. In 2019, it was the 189th most commonly prescribed medication in the United States, with more than 3 million prescriptions. In the United Kingdom it is less preferred to antimuscarinic medication such as oxybutynin.

Medical uses
Mirabegron is used is in the treatment of overactive bladder. It works equally well to antimuscarinic medication such as solifenacin or tolterodine. In the United Kingdom it is less preferred to these agents.Mirabegron is also indicated to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.

Adverse effects
Adverse effects by incidence:Very common (>10% incidence) adverse effects include:

Elevated blood pressureCommon (1–10% incidence) adverse effects include:

Dry mouth
Nasopharyngitis
Urinary tract infection (UTI)
Headache
Influenza
Constipation
Dizziness
Joint pain
Cystitis
Back pain
Upper respiratory tract infection (URTI)
Sinusitis
Diarrhea
High heart rate
Fatigue
Abdominal pain
Neoplasms (cancers)Rare (<1% incidence) adverse effects include:

Palpitations
Blurred vision
Glaucoma
Indigestion
Gastritis
Abdominal distension
Rhinitis
Elevations in liver enzymes (GGTP, AST, ALT and LDH)
Renal and urinary disorders (e.g., nephrolithiasis, bladder pain)
Reproductive system disorders (e.g., vulvovaginal pruritus, vaginal infection)
Skin and subcutaneous tissue disorders (e.g., urticaria, leukocytoclastic vasculitis, rash, pruritus, purpura, lip edema)
Stevens–Johnson syndrome associated with increased serum ALT, AST and bilirubin
Urinary retention

References
Further reading
Sacco E, Bientinesi R (December 2012). "Mirabegron: a review of recent data and its prospects in the management of overactive bladder". Therapeutic Advances in Urology. 4 (6): 315–24. doi:10.1177/1756287212457114. PMC 3491758. PMID 23205058.
Tyagi P, Tyagi V, Chancellor M (March 2011). "Mirabegron: a safety review". Expert Opin Drug Saf. 10 (2): 287–94. doi:10.1517/14740338.2011.542146. PMID 21142693. S2CID 207487296.

External links
"Mirabegron". Drug Information Portal. U.S. National Library of Medicine.